{"id":"W2123437999","doi":"10.1158/1078-0432.ccr-10-0822","title":"Phase I Dose Finding Studies of Obatoclax (GX15-070), a Small Molecule Pan-BCL-2 Family Antagonist, in Patients with Advanced Solid Tumors or Lymphoma","year":2010,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Cell death mechanisms and regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":103,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Tolerability; Medicine; Regimen; Lymphoma; Pharmacokinetics; Maximum tolerated dose; Antagonist; Nausea; Pharmacology; Toxicity; Internal medicine; Adverse effect; Oncology; Receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001463322,0.001344451,0.0013254,0.0004083348,0.0002911121,0.0005246141,0.000851237,0.0009351403,0.002420024],"category_scores_gemma":[0.0007518418,0.0003926872,0.0007712315,0.0002971157,0.00099807,0.0006173871,0.0003358792,0.002344395,0.0004565302],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009420795,"about_ca_system_score_gemma":0.001336976,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000602697,"about_ca_topic_score_gemma":0.001641395,"domain_scores_codex":[0.9996021,0.0002109661,0.0000234109,0.00004855946,0.00004175744,0.00007323951],"domain_scores_gemma":[0.9993653,0.0001487224,0.0001358658,0.00005172064,0.00003269049,0.0002658703],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4167791,0.1033244,0.02126961,0.001369191,0.001265281,0.0008925524,0.0008753196,0.007050201,0.2716443,0.000762724,0.004584766,0.1701825],"study_design_scores_gemma":[0.2272974,0.7391016,0.01376493,0.00003405999,0.0002556234,0.0004307146,0.0000665907,0.001085571,0.01536846,0.0001466201,0.002425193,0.00002328944],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.995787,0.001061245,0.0004851104,0.0001939564,0.00003020263,0.001390731,0.0002436185,0.00006125055,0.0007469516],"genre_scores_gemma":[0.992722,0.001044529,0.002001718,0.000404838,0.00006966814,0.001595292,0.001140257,0.0000133007,0.001008357],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002420024,"threshold_uncertainty_score":0.00809586,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1277390090834309,"score_gpt":0.4825296105298467,"score_spread":0.3547906014464158,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}